

HPTN 108/ PAUSE STUDY Brief

21 August 2024

Heading/Title (Option 1)

HPTN 108 Study: Pausing Antiretroviral Treatment Under Structured Evaluation (PAUSE Study)

Heading/Title (Option 2)

A Phase 1, Randomized, Placebo-controlled Study of the Safety, Antiviral and Immunomodulatory Activity of Broadly Neutralizing Antibodies 3BNC117-LS-J and 10-1074-LS-J in Combination in ART-treated Adults in sub-Saharan Africa giving with HIV during a Monitored Analytical Treatment Interruption

Overview

The HPTN 108 Study, also known as the PAUSE Study, is a Phase 1, randomized, placebo-controlled trial investigating the safety, efficacy and tolerability of the combination of two long-acting broadly neutralizing antibodies (bNAbs), 3BNC117-LS-J and 10-1074-LS-J, in ART-treated adults living with HIV in sub-Saharan Africa. The study focuses on whether these bNAbs, administered through intravenous infusion, will be safe, well-tolerated, and capable of maintaining durable viral suppression in the absence of antiretroviral therapy (ART) during a monitored analytical treatment interruption (ATI).

Study Objectives

The primary objective of this study is to determine whether the combination of 3BNC117-LS-J and 10-1074-LS-J can effectively maintain viral suppression in people living with HIV while pausing ART, provided the bNAbs remain at therapeutic levels. The study will assess both the safety and efficacy of this innovative treatment strategy, which could represent a significant advancement in HIV management if proven effective.

Study Location

The HPTN 108 Study will be conducted at the Wits RHI Ward 21 Clinical Research Site, situated in the Johannesburg Region F community. Wits RHI has a strong track record in conducting cutting-edge HIV research, and this study aligns with its ongoing mission to improve health outcomes in the region.



Study Investigators:

- Prof. Sinead Delany-Moretlwe
- Dr. Carrie Matthew

Are you interested in being part of a study to learn about bNAbs in HIV Treatment?

- Interested in research participation
- 18-65 years of age
- Living in Johannesburg
- HIV positive and stable on ART for 2 or more years
- Not pregnant or breastfeeding
- Willing to use reliable contraception

The HPTN 108 Study represents a critical step forward in exploring alternative approaches to HIV treatment that could potentially reduce the need for continuous ART, improving the quality of life for people living with HIV in sub-Saharan Africa. Stay tuned for updates as the study progresses.

